Multicenter study of impact of oophorectomy on breast cancer survival in patients with CHEK2 mutations

A multicenter study in Poland evaluated the impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. The study included 839 patients with a CHEK2 mutations and 839 matched patients without a CHEK2 mutation. The 15-year survival was 76.6% for the mutation carriers versus 78.8% for the non-carrier control patients (p=0.61). Among CHEK2 mutation carriers, the 15-year survival for women who had an oophorectomy was 86.3% versus 72.1% for women who did not have an oophorectomy (aHR 0.59; p=0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% versus 77.6% for patients who did not have an oophorectomy (p=0.90). The authors conclude that among women with breast cancer and a CHEK2 mutation, oophorectomy was associated with a reduced risk of death from breast cancer.